Hospitals nationwide could lose half a billion dollars in federal funding for uninsured patients next year under the national health overhaul — a loss that will hit especially hard in states that decided against expanding Medicaid coverage. Cuts could jump to $4 billion in 2020, according to estimates released Monday by federal health officials.
Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. Merck also saw stronger sales of materials for liquid-crystal displays and raised its profit forecast.
Many parents are still using cold medications for their young children despite warnings against the practice. Anna Mathews and Emory University pediatric emergency medicine fellow Sarah Lazarus join Lunch Break with a look at the latest research.
Model M6 and M50 liquid handling pumps are a new generation of pumps for precision handling of liquids and/or gases, producing a bidirectional pulseless flow with a range of over six orders of magnitude. A replacement for syringe pumps, the Cheminert pumps eliminate the need for refill cycles and syringe changes.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
A subsidiary of India's largest pharmaceutical company has agreed to pay $500 million in fines and civil penalties for selling adulterated drugs and lying about tests of the medications to federal regulators, the U.S. Justice Department said Monday.
Kilo-lab size conical vacuum dryer/mixer machine matches the special requirements in the lab with regard to the software program data recording, measurement points, outfit and use, and offers modular design, maximum flexibility and mobility, applications can be carried out on drying processes under vacuum and other procedures such as mixing and homogenizing, degassing, moistening and so forth.
The VirTis Benchtop Pro with Omnitronics freeze dryer has been engineered with the research scientist in mind. Traditional time losses incurred from lengthy condenser defrost and clean-up procedures are minimized with the new hot-gas defrost facility on the BenchTop Pro.
The simplefilter is designed for many pharmaceutical applications such as: hydrogenation, carbon filtration, catalyst recovery, pre-filter for micro-filtration, APIs and intermediate filtration.
The Bella Series 543 mixer/dryer/cooler offers an improved method for drying or cooling powders, granulates and filter cakes. The Bella dryer can be used for drying, mixing, spraying, agglomerating and cooling in the same unit without additional equipment or costs.
The blending system allows homogeneous blending of dry powder batches with its patented blending elements mounted to the inside of the container lid. The blending procedure can be scaled up from 4 – 12,000 liters.
The new range of Aptamer Protein Precipitation Kits bind with unmatched high specificity and affinity to target molecules. The new Aptoprecipitation (AP) / Co-aptoprecipitation (Co-AP) Kits are aptamer based protein precipitation kits designed to provide easy, quick and consistent protein precipitation.
A new study about a popular drug used to help so many moms speed up labor and could have some potentially negative effects. According to researchers, pitocin showed a potential link to some full term infants having increased admissions to neonatal intensive care units.
The government has halted a study testing treatments for a brain condition that can cause strokes after early results suggested invasive therapies were riskier than previously thought. The condition involves a kind of tangle in the brain called an arteriovenous malformation, or AVM. Arteries and veins grow knotted together until eventually some of them burst, causing a bleeding stroke.
Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.